Doxycycline Delayed-Release Capsule (Oracea)


FDA Approved Indications:
  • Treatment of only inflammatory lesions (papules and pustules of rosacea in adult patients)
Prior authorization criteria:
  • Treatment of pustular/papular rosacea confirmed by medical record documenation, AND
  • Patient is at least 18 years of age, AND
  • Patient has tried and failed preferred topical agent (e.g., metronidazole gel)
  • 40 mg once daily
  • Efficacy of Oracea beyond 16 weeks and safety beyond 9 months have not been established


WHA is closely monitoring the Coronavirus Disease 2019 (COVID-19). Learn more about COVID-19.